Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $189.4 million.

  • Anika Therapeutics' Liabilities and Shareholders Equity fell 18.14% to $189.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $770.5 million, marking a year-over-year decrease of 25.08%. This contributed to the annual value of $202.7 million for FY2024, which is 25.09% down from last year.
  • As of Q3 2025, Anika Therapeutics' Liabilities and Shareholders Equity stood at $189.4 million, which was up 0.94% from $187.7 million recorded in Q2 2025.
  • In the past 5 years, Anika Therapeutics' Liabilities and Shareholders Equity registered a high of $363.1 million during Q2 2021, and its lowest value of $187.7 million during Q2 2025.
  • Over the past 3 years, Anika Therapeutics' median Liabilities and Shareholders Equity value was $262.7 million (recorded in 2024), while the average stood at $254.1 million.
  • As far as peak fluctuations go, Anika Therapeutics' Liabilities and Shareholders Equity climbed by 0.46% in 2022, and later declined by 29.48% in 2024.
  • Anika Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $347.5 million in 2021, then climbed by 0.46% to $349.1 million in 2022, then fell by 22.48% to $270.6 million in 2023, then dropped by 25.09% to $202.7 million in 2024, then decreased by 18.14% to $189.4 million in 2025.
  • Its last three reported values are $189.4 million in Q3 2025, $187.7 million for Q2 2025, and $190.6 million during Q1 2025.